MedTrace Logo

Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study

NCT07264426 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-04-23

No results posted yet for this study

Summary

The aims of this study are to assess the real-world effectiveness of efgartigimod in treating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), describe the "treatment journey" of participants with CIDP, and assess the utilization of health care services among adult participants with CIDP who initiate treatment with efgartigimod.

As this is a noninterventional study, treatment choices and decisions will be left to the discretion of participants and their physicians, according to the standard of care.

Each participant will be prospectively followed for up to 2 years from the date of initial administration of efgartigimod.

Conditions

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP
  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)

Interventions

BIOLOGICAL

Efgartigimod PH20 SC

Efgartigimod treatment per country-specific label for the treatment of CIDP

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-11
Primary Completion
2029-10-31
Completion
2029-10-31
FDA Drug
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264426 on ClinicalTrials.gov